India's pharmaceutical companies are facing a series of regulatory and other hurdles, exacerbated by self-inflicted errors and badly conceived government policies that will hobble the $30 billion generic drug sector. Some companies have started to work together to raise quality and iron out regulatory compliance problems, but others have yet to make serious efforts to help themselves. That needs to change quickly.
India's pharmaceutical prescription is unhealthy
Generic drug companies must confront multiple challenges to survive